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ABSTRACT
Purpose: To determine treatment-related acute toxicity rates in patients with locally
advanced cervical cancer treated by oral celecoxib, i.v. cisplatin and 5-FU, and
concurrent pelvic radiation therapy.
Methods and Materials: Eligible patients on this RTOG Phase I-II study for
advanced cervix cancer included FIGO Stage IIB-IVA or patients with FIGO Stage
IB through IIA with biopsy proven pelvic node metastases ortumor size >5 cm.
Patients were treated with pelvic radiotherapy and brachytherapy. Celecoxib was
prescribed at 400 mg twice daily beginning on day 1 for 1 year. Cisplatin (75
mg/m2) and 5-FU (1g/m2 for 4 days) were administered every 3 weeks times 3. The
primary end point of the study was treatment related toxicity.
Results: Between August 2001 and March 2004, 84 patients were accrued to the
study and 77 patients were evaluable for toxicity. Regarding the primary end point,
toxicities were observed in the following areas: blood/bone marrow (16),
gastrointestinal (14), pain (7), renal/genitourinary (6), cardiovascular (3),
hemorrhage (1), and neurologic (1). For the first 75 evaluable patients, a toxicity
failure was identified in 36 patients for a rate of 48%.
Conclusions: Celecoxib at 400 mg twice daily together with concurrent cisplatin and
5-FU and pelvic radiotherapy has a high incidence of acute toxicities. The most
frequent toxicities were hematologic. Albeit, the toxicity was deemed excessive in
this trial, the rate of toxicities was not too different compared to other recent
experiences with concurrent chemoradiation for advanced cervix cancer.
Keywords: Cervix, Radiation therapy, Celecoxib, Acute toxicity.
INTRODUCTION
Chemoradiation has been shown to improve overall survival in women with advanced
cervix cancer (1---7). Despite a dramatic improvement in overall survival, approximately
one-third of patients with advanced cervix cancer will have failed therapy within 2 years
(3). Thus, improvement in the treatment of advanced cervix cancer is desperately needed.
In the United States, approximately 10,370 new cases of cervical cancer will be
diagnosed and of these, greater than 3,710 will die from the disease (8). Worldwide,
cervix cancer continues to be the second most frequent cause of cancer and cancer-related
mortality in women. Only breast cancer has a higher incidence and mortality (9). Thus,
improvements in survival rates of women with cervix cancer may translate into a
significant impact on women’s health worldwide. Targeted therapies including
Cyclooxygenase-2 (COX-2) inhibition may be promising approaches to achieve this end.
COX-2 is cytokine inducible whereas cyclooxygenase-1 is constitutively expressed.
Enhanced COX-2 expression has a key role in the development of edema by impeding
blood flow and causing immunomodulation that is observed in pathologically altered
disease states (10---11). COX-2 is over expressed in a wide variety of different tumors
including cervix carcinomas and is associated with a poor outcome (12---15). Inhibition of
COX-2 has been found to diminish tumor growth in a myriad of ways including
promoting apoptosis, inhibiting vascular endothelial growth factor (VEGF), inhibiting
new vessel growth, and sensitizing cells to radiation (16---24). Animal models have shown
that COX-2 inhibition will improve the response to radiotherapy without markedly
affecting normal tissue radiation response (25--26). Radiation of cells in vitro have also
shown to increase COX-2 expression and its enzymatic product, prostaglandin E2
(PGE2) (27). Additionally, a Phase III randomized trial in familial adenomatous
polyposis patients showed that 6 months of Celecoxib versus placebo significantly
diminished the size and number of polyps (28). Thus, we proceeded to perform a trial in
patients with advanced cervical carcinoma using i.v. cisplatin and 5-fluorouracil (5-FU)
chemotherapy with concurrent celecoxib. The primary goal was to determine treatment
related toxicity.
METHODS AND MATERIALS
Patient eligibility
Patients were considered eligible who had histologic proof of squamous cell carcinoma,
adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, International
Federation of Gynecology and Obstetrics (FIGO) Stage IIB through IVA disease or
patients with FIGO Stage IB to IIA who have biopsy proven pelvic lymph node
metastasis or tumor size 5 cm. Patients were required to have a Zubrod performance
status of 0 to 2 and no disease outside of the pelvis. Laboratory values must be as
follows: White blood cell count greater than or equal to 3000/mm3, absolute neutrophil
count greater than 1500 mm3, platelets greater than 100,000 mm3, total bilirubin less than
1.5 mg/dl, serum creatinine less than 1.5 mg/dl, aspartate aminotransferase or alanine
aminotransferase less than or equal to 2.5× the upper normal limit, serum calcium less
than 1.3× the institutional upper normal limit, creatinine clearance greater than or equal
to 50 cc/min. All patients were required to sign a study-specific informed consent.
Patients were considered ineligible for the protocol if any of the following applied: Prior
or simultaneous malignancy unless disease free greater than 3 years, medical illness
preventing the use of full dose chemotherapy, carcinoma of the cervix with histology
showing small cell, carcinoid cell, clear cell, adenoid cystic carcinoma, previous medical
or psychiatric illness, which would prevent informed consent, patients known to be
infected with human immunodeficiency virus, prior surgery for carcinoma of the cervix
other than biopsy, patients with para-aortic disease, previous radiation or systemic
therapy, previous hypersensitivity to celecoxibs, patients who have recently been on any
COX-2 inhibitor within 2 months, taking Dilantin or lithium, active cardiac disease,
patients with active gastrointestinal ulcers, inflammatory bowel disease, and pregnant or
lactating females. Additionally, patients were required to have a chest X-ray within 6
weeks of entry, and a CT or MRI of the pelvis at least to the level of the renal vessels
with contrast within 6 weeks before study. Cystoscopy and sigmoidoscopy were
suggested for bulky lesions and pregnancy tests were required for premenopausal
females.
Radiation therapy
Radiation therapy was 45 Gy to the whole pelvis in 5 weeks in 25 fractions. A four-field
technique was recommended particularly when the beam energy was less than 15 MV.
The involved lateral parametrium or pelvic lymph nodes were recommended to receive a
boost to achieve a total dose of 60 Gy. Techniques to limit dose to small bowel were
suggested including prone positioning and a full bladder. The superior border of the
pelvic field was L4/5 and the inferior border was a transverse line below the obturator
foramen. The lateral border was 2 cm lateral to the widest true pelvic diameter. On the
lateral portal, the anterior border was placed anterior to the symphysis pubis and at least 1
cm anterior to the common iliac nodes at L4--5, and for the posterior border the entire
sacrum was recommended or at a minimum a 3 cm margin posterior to the greatest extent
of disease.
Low dose rate (LDR) or high dose rate (HDR) brachytherapy was permitted. For LDR, 2
insertions were recommended delivering a total RT dose of 85 Gy to point A, and the
interval between the 2 insertions was to be 1 to 3 weeks. The third cycle of chemotherapy
was recommended to be delivered with the second brachytherapy insertion if LDR was
utilized. For patients receiving HDR brachytherapy, 5 fractions of 6 Gy each to point A
were recommended. One fraction a week was recommended as early as Week 3. Two
insertions per week were allowed given the fractions were separated by 72 h. Tandem
and ovoids or a tandem and ring were recommended for HDR brachytherapy. Interstitial
brachytherapy was allowed to treat distal vaginal disease that cannot be covered with
intracavitary techniques. Multiple points consistent with ICRU 38 were evaluated for
brachytherapy dosimetry including point A, point B, bladder, rectum, and vaginal
surface. Treatment was to be completed within 56 days. The Radiologic Physics Center
in Houston, Texas evaluated all implants and provided quality assurance to all centers.
Chemotherapy
Patients received cisplatin chemotherapy after i.v. hydration at 75 mg/m2 with a
maximum dose of 150 mg on Days 1, 22, and 43 of RT delivery. 5FU was administered
at 1 gm/m2 for 4 days either by bolus infusion or continuous infusion on Days 2---5, Days
23--26, and Days 44---47. Hematopoietic growth factors were permitted, but not
specifically endorsed. Celebrex™ was to start on Day 1 of radiotherapy (RT), and
continue daily for 12 months (400 mg p.o. b.i.d., total 800 mg daily). The AM dose was
to be given 3 h before RT. If LDR brachytherapy was utilized, the third cycle of
chemotherapy was to be delivered at the time of the implant.
Statistics
The primary endpoint of treatment-related toxicity for this trial included the following:
(1) Grade 3 nausea and vomiting or diarrhea despite medical intervention; (2) Grade 4
neutropenia or leukopenia persisting for greater than 7 days; (3) Grade 3 anemia or
thrombocytopenia; and (4) Grade 3 gastrointestinal (GI), renal, cardiac, pulmonary,
hepatic and neurologic toxicity. Chemotherapy and acute RT toxicities were scored
according to the Common Toxicity Criteria version 2.0 (CTC v. 2.0) criteria. Late RT
toxicities were scored according to the Radiation Therapy Oncology Group/European
Organisation for Research and Treatment of Cancer (RTOG/EORTC) Late Morbidity
Scoring Schema. Based on the chemoradiation arm from RTOG 90--01, about 22% of
patients in the chemoradiation arm experienced the 4 toxicities above. Assuming 20% of
the toxicity is considered tolerable, we consider a toxicity rate of 35% or above as
excessive. Seventy-five evaluable cases provided a 5% chance of rejecting the treatment
when the severe toxicity rate is 20%, and 90% chance of rejecting the treatment when the
severe toxicity rate is 35%. Considering 10% ineligible or lack-of-data cases, the total
sample size was set at 83. Early stopping rules for excessive toxicity were in place as
well as routine interim reporting every 6 months. All eligible patients starting protocol
therapy will be included in the analyses. Based on Flemming’s method and assuming that
the study did not meet an early stopping rule, the treatment will be rejected for excessive
toxicity if there are 34 or more cases with the primary endpoint specified toxicity (29).
Table 1. Patient characteristics (n = 77)
_____________________________________
Age (years)
Median 45
Range 24---68
__________________________________________
n %
Zubrod
0 57 74
1 18 23
2 2 3
FIGO Stage
IB 18 23
IIA 3 4
IIB 40 52
IIIB 13 17
IVA 3 4
___________________________________________
RESULTS
Between August 2001 and March 2004, 84 patients were accrued to the study and 77
patients were evaluable for toxicity. Four patients were ineligible, 2 received no protocol
therapy and 1 withdrew consent. The median follow-up for all patients for this analysis is
18 months. The median age was 45 years (Table 1). The stage distributions were: IB
23%; IIA 4%; IIB 52%; IIIB 17%, and IVA 4%. In December of 2004, the drug company
alerted RTOG that an excess risk of cardiovascular complications was observed on
previous Phase III trials employing COX-2 inhibitors. All cardiovascular complications
were reviewed and none were found to be likely related to celecoxib; nevertheless, due to
a small number of patients (7) potentially remaining on the maintenance phase (celecoxib
therapy only) of the protocol at that time it was deemed reasonable to discontinue
maintenance celecoxib therapy at that time. The potential harm was felt to be greater than
the potential benefit for the few remaining weeks of celecoxib therapy.
A four-field external beam technique was used in 93%, and an AP:PA technique in 7%.
Protocol treatment compliance is shown in Table 2. Radiotherapy and brachytherapy was
performed per protocol or with a minor deviation in 79% and 82% of patients,
respectively. No implant was delivered in 8 of 77 patients (10%). This was the first
RTOG cervix cancer trial that permitted HDR brachytherapy and it was utilized in 35%
of patients receiving brachytherapy. The median dose to Point A for patients that received
a LDR brachytherapy was 84.98 Gy, while the median doses to bladder and rectum were
65.50 Gy and 66.00 Gy, respectively. For patients that received HDR brachytherapy, the
median doses to Point A, bladder and bowel were 75.00 Gy, 62.05 Gy, and 62.39 Gy,
respectively. Biologically equivalent dose calculations were used employing the linear-
quadratic formula assuming an alphabeta ratio of 10 for tumors and 2 for normal tissues
(30). For acute reacting tissues or tumor this yielded an equivalent biologically equivalent
dose of 101.1 Gy (BED Gy10) for both HDR and LDR; however, the biologically
equivalent doses for late responding tissues were greater for HDR than LDR; 205.5 BED
Gy2 and 165.5 BED Gy2, respectively. The median overall RT treatment time in this trial
was 44 days, ranging from 31 to 74 days, which corresponded to 41 days (31---74 days)
for LDR patients and 45 days (38---70 days) for HDR patients.
Chemotherapy compliance was more variable with only 7% of patients receiving full
protocol dose of all 3 cycles. Three cycles of at least 80% of the protocol specified
cisplatin and 5-FU doses each were able to be administered in 57% and 40% of patients,
respectively. Three cycles of chemotherapy was delivered to 65% of patients that
completed radiotherapy treatment. The median dose of cisplatin was 355 mg. Celecoxib
compliance was not high, particularly in the maintenance phase after chemoradiation,
about 20% reportedly discontinued due to toxicity. The protocol specified 1 year of
celecoxib at 400 mg bid (800 mg daily dose) equates to 292,000 mg, and the first
quartile, median, and third quartile received were 20,000, 64,800, and 196,400,
respectively. The doses of celecoxib were recorded in a pill diary after instructions from
member institutions.
Table 3 describes chemotherapy and acute radiotherapy toxicity, which was graded
according to the CTC v. 2.0 criteria. The most frequent Grade 3 and 4 combined toxicity
was hematalogic (40/77 patients), while the most frequently observed Grade 3 toxicities
were GI, hematalogic, skin, and metabolic. The worst nonhematalogic toxicity were
observed in 53% and 13% of patients for Grades 3 and 4, respectively.
Table 4 describes late radiotherapy toxicity, which was scored according to the
RTOG/EORTC Late Morbidity Scoring Scheme, with a relatively short median follow up
of 18 months. The most common form of late radiotherapy toxicity was genitourinary
followed by gastrointestinal. For Grade 3 or greater late toxicities we observed 5 bladder
or genitourinary toxicities, 2 GI toxicities, 1 bone pain, 1 pelvic fracture, and 1 vaginal
necrosis.
In Table 5, primary end-point toxicities are reported with toxicities observed in the
following areas: blood/bone marrow (16), GI (13), pain (7), renal/genitourinary (6),
cardiovascular (3), hemorrhage (1), and neurologic (1). Fortyseven toxicities were
observed in 36 of the first 75 patients (48%) and in 36 of all 77 patients (47%). Thus,
exceeding the previously defined safe limit of 35%.
Table 6 describes all acute GI toxicities greater or equal to Grade 3 in recent trials
employing chemoradiation. In our study, we observed a greater than or equal to Grade 3
GI toxicity in 45% of patients. This is elevated above other experiences in cooperative
groups, either with cisplatin or 5-FU and cisplatin-based chemotherapeutic regimens.
Table 2. Radiotherapy, brachytherapy, and chemotherapy compliance (n = 77)
________________________________________________________________________
Radiotherapy Brachytherapy Chemotherapy
n % n % n %
________________________________________________________________________
Per protocol 54 70 51 66 20 26
Variation acceptable 7 9 12 16 40 52
Deviation unacceptable 11 14 5 6 2 3
Incomplete 5 6 9 12 15 19
________________________________________________________________________
For Radiotherapy, one patient was scored as Incomplete due to progression, and 4
patients refused to continue with protocol treatment. For Brachytherapy, eight patients
did not receive an implant and one was not evaluable.
Table 3. Chemotherapy and acute radiotherapy toxicity (n = 77)
________________________________________________________________________
Grade
__________________________________________
1 2 3 4
________________________________________________________________________
Allergy/immunology 1 1 3 0
Auditory/hearing 0 6 2 0
Blood/bone marrow 9 23 22 18
Hemoglobin decreased 4 11 4 2
Leukopenia 1 8 12 8
Lymphopenia 0 2 0 0
Neutropenia 0 0 3 7
Packed red blood cell
transfusion 0 0 2 0
Platelet count decreased 3 2 1 1
Hematologic-Other 1 0 0 0
Cardiovascular (arrhythmia) 0 0 0 1
Cardiovascular (general) 6 1 2 0
Constitutional symptoms 20 14 6 0
Dermatology/skin 10 15 14 0
Endocrine 2 4 0 0
Gastrointestinal 9 26 33 2
Hemorrhage 16 2 2 0
Hepatic 11 10 0 0
Infection/febrile neutropenia 3 5 5 3
Metabolic/laboratory 22 3 10 3
Musculoskeletal 1 1 0 0
Neurology 10 7 3 0
Ocular/visual 2 1 0 0
Pain 7 19 8 2
Pulmonary 2 3 0 0
Renal/genitourinary 22 15 7 0
Sexual reproductive function 1 3 0 0
Worst non-hematologic 6 18 41 10
(8%) (23%) (53%) (13%)
Worst overall 2 9 40 24
(3%) (12%) (52%) (31%)
________________________________________________________________________
Table 4. Late RT toxicity (n = 75)
________________________________________________________________________
Grade
__________________________________________
1 2 3 4
________________________________________________________________________
Bladder 6 3 3 2
Bone 2 2 1 1
Kidney 2 0 0 0
Other 6 11 1 0
Skin 6 0 0 0
Small/large Intestine 13 7 2 0
Worst overall 14 15 7 3
(18%) (19%) (9%) (4%)
________________________________________________________________________
Abbreviation: RT = radiotherapy.
Table 6. Comparison of > Grade 3 GI toxicities
________________________________________________________________________
Acute GI Late GI
toxicity toxicity
Study Regimen Grade > 3 Grade > 3
________________________________________________________________________
Current 5FU, CDDP, and 45.4% 2.7%
Celecoxib
RTOG 9001 5FU and CDDP 8.7% 12.6%
GOG 85 5FU and CDDP 7.7% NR
GOG 120 5FU, CDDP, and 18% NR
Hydroxyurea
GOG 120 CDDP weekly 12% NR
GOG 123 CDDP weekly 14.2% NR
NCIC CDDP weekly 12.6% 4.8%
GOG 165 CDDP weekly 25% NR
GOG 165 Ci5FU 19% NR
________________________________________________________________________
Abbreviations: CDDP = cisplatin; 5FU = 5-fluorouracil; GOG = Gynecologic Oncology
Group; GI = gastrointestinal; NCIC = National Cancer Institute of Canada; RTOG =
Radiation Therapy Oncology Group
DISCUSSION
COX-2 inhibitors have been combined with chemotherapy in a number of settings.
Celecoxib has been combined with RT in a number of settings including the treatment of
lung, CNS, and GI malignancies and shown to be safe (31--34). In a Phase I study
performed at MD Anderson Cancer Center in unfavorable performance nonsmall lung
cancer patients treated to 66 Gy in 33 fractions with concurrent celecoxib, the maximally
tolerated dose was not reached; and 800 mg bid of celecoxib was observed to be safe
(31). Celecoxib related toxicity was observed in 3 of 47 patients in their study. The
efficacy of celecoxib in this trial along with chemoradiation is scheduled to be evaluated
subsequently. One pilot study showed reasonable promise in the treatment of advanced
pancreatic carcinoma cancer without increased toxicity (35). Whereas other studies have
shown increased toxicity without increased efficacy in the treatment of GI malignancies
with chemotherapy (36, 37).
The primary toxicity in our study was hematologic. Nevertheless, we experienced a
significant rate of GI toxicity in this study. Although we observed a Grade 3 rate of GI
toxicity in 43% (33/77) of patients, the toxicities observed were principally diarrhea,
nausea, and dehydration, many of which were able to be controlled with medical
intervention. We did not experience a significant number of adverse events attributable
to upper GI toxicity which more readily could implicate the celecoxib therapy. In some
trials, coxibs showed no more upper GI toxicity than placebo while other studies showed
no difference in GI bleeding rates compared with nonsteroidal anti-inflammatory agents
(38--40). In studies such as this, it is difficult to ascribe toxicities to a single agent when
patients are receiving a complex regimen of external beam and intracavitary radiotherapy
and chemotherapy with 5-FU and cisplatin. Although the acute toxicity in this trial was
moderately high indicating the toxicity of the regimen, it was similar to the overall rate of
Grade 3 or greater toxicity seen in Gynecologic Oncology Group (GOG) 165 with either
pelvic RT with weekly cisplatin or with continuous infusion 5-FU. The worst overall
Grade 3 and 4 toxicity observed in this trial with daily celecoxib, cisplatin and 5-FU was
52%, compared with 58% and 32% observed with weekly cisplatin and continuous
infusion 5-FU in GOG 165, respectively (Table 6) (41). The higher rate of toxicities
reported herein and by Lanciano et al. appear to be higher than the original reports that
provided the NCI alert indicating the benefit seen with the cisplatin based regimens in the
radiotherapeutic management of women with advanced cervix cancer (1---6, 41). This may
be in part related to selection bias. An interesting study by Torres from MD Anderson
demonstrated increased toxicity seen in patients treated more recently at their facility
compared with patients treated on randomized trials in the 1990s (42).
In this trial, our a priori safety boundary was exceeded. It is possible that this is a
substantially toxic regimen, or that our population did not match our comparison group
well from the chemoradiation arm of RTOG 9001. If promising efficacy is seen with this
regimen and no substantial increase in late toxicities, it may be reasonable to further test
celecoxib together with chemoradiation in the treatment of carcinoma of the cervix. We
recommend continued accrual to trials evaluating different biologic agents along with
chemoradiotherapy or novel approaches to the treatment of advanced cervix cancer.
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